View the 50 largest pharmaceutical companies in the world listings here
Jazz Pharmaceuticals
Rank: 40
2024 Revenues ($USD) : $4.07B
Jazz Pharmaceuticals delivered record total revenues of $4.1B in 2024, representing a 6% YoY increase, while generating over $1.4B in cash from operations. Growth was driven by strong performance across the portfolio, particularly Xywav (up 16% to $1.47B) and Epidiolex/Epidyolex (up 15% to $972.4M). The recent launch of Zihera in December 2024 following FDA approval represents another growth opportunity in the company's expanding oncology portfolio.